docetaxel,darolutamide
bayer
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'arasens', ' daro ']
efficacy &amp; safety of daro + adt + doce by disease volume and disease risk in ph 3 arasens rct #gu23 77% high-volume, 70% high-risk, 23% low-volume, 30% low-risk daro + adt + doce prolonged os regardless of high- or low-volume disease - high volume: hr 0.69, 95% 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday